Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
股海静观陶
发表于 2024-5-13 09:44:09
1332
0
0
Southern Finance and Economics, May 13 (Xinhua) - Zaiding Pharmaceutical Hong Kong Stock Exchange announced that the National Medical Products Administration of China has approved the use of reprotinib for the treatment of ROS1 positive non-small cell lung cancer patients.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Pfizer Besponsa has been approved by the FDA for the treatment of pediatric patients
- The latest research: Wegovy is also effective for patients with diabetes and heart failure
- Xiaomo bearish US stock market earnings season: Positive sentiment has been digested ahead of schedule, with most companies expecting a decline in profits
- Positive news keeps rising in major global markets, with multiple indices reaching historic highs!
- AstraZeneca lung cancer targeted drug Teresa has been approved for new indications in China
- American brain computer company pioneers: Empowering patients with communication skills through OpenAI models
- Baidu Health Platform has attracted over 300000 doctors to join and serve over 210 million patients
- Incidence rate of lung cancer death in women is higher than that in men
- AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
